GH Axis Research, Three Ways In

The short version

NXT LVL Peptides is a research digest on Growth Hormone Axis research peptides — three compounds studied for their effect on growth hormone (GH) and its downstream hormone, IGF-1. GH and IGF-1 together regulate fat metabolism, lean mass, and tissue repair. This pairing is what people mean by the GH axis.

The three compounds here take different routes to the same axis. CJC-1295 is a long-acting analog of GHRH, the natural signal that triggers GH release. CJC-1295 / Ipamorelin adds a second pathway — the ghrelin receptor — on top of that signal. Tesamorelin is a separate GHRH analog, and the only one of the three with FDA approval, for a narrow, HIV-specific indication.

None of these compounds is approved for general body-composition use. This site reports what the published research found, states the population and duration each finding came from, and stops. No dose is recommended here.

GH-axis peptides studied for body composition

Growth hormone does two jobs relevant to body composition. It drives lipolysis — the release of fat from storage, with some preference for visceral fat over subcutaneous fat. And it raises IGF-1, which supports lean-tissue maintenance and repair.

The compounds on this desk stimulate that axis indirectly, through the pituitary gland, rather than supplying GH itself. CJC-1295 does this by mimicking GHRH and resisting the enzyme that normally breaks it down — the DAC variant extends that action from minutes to days by binding a blood protein. CJC-1295 / Ipamorelin adds a second, independent receptor pathway to the same pituitary cell, aiming for a larger combined pulse. Tesamorelin takes the GHRH-analog approach on its own, and has the clinical trial record to show what that approach does in a defined population — visceral and hepatic fat reduction in HIV-associated lipodystrophy.

The pattern across all three: stimulate the axis upstream, and GH/IGF-1 downstream effects follow. What differs is duration of action, receptor count, and — critically — whether a compound has cleared a regulatory approval process.

What are research peptides?

Peptides are short chains of amino acids — smaller than proteins, built from the same building blocks. The three on this desk are GHRH analogs or GH secretagogues: synthetic molecules that mimic or amplify a hormone signal the body already produces.

Research peptide is a supplier classification, not a clinical one. It means the material is sold for laboratory research, not for human use, and it has not gone through the trial and manufacturing oversight an approved drug requires. Tesamorelin is the exception here — it exists both as an approved pharmaceutical and, separately, as research-grade material sold outside that approval. CJC-1295 and CJC-1295 / Ipamorelin have no approved form at all.

This distinction matters for reading every page on this site: an approved indication and a research report are not the same category of evidence.

How this desk reads the evidence

Every claim on this site traces to a numbered citation on the references page — a peer-reviewed trial, meta-analysis, or regulatory drug-safety monograph. Where a finding comes from a small early-phase study rather than a large trial, this site says so. Where a compound has no approved indication, this site says that too, plainly, on every page it appears.

Community-reported effects appear only where they exist, labeled as anecdotal, and never attached to a dose. Cautions come from the mechanism and the cited literature, not from speculation. Read the comparison page for the fastest way to see how the three compounds differ.